RxDoctor Payments Data

James Bumgartner, MD

Neurology · Charleston, SCNPI 1477522845

Payments from drug & device makers

$9,706in general payments, 2019–2025

Across 611 payments — averaging $15.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • AbbVie$1K
  • UCB, Inc.$583
  • Bristol Myers Squibb$556
  • Pfizer$483
  • Sunovion Pharmaceuticals Inc.$384
  • plus $4K from 50 others

What the payments were for

  • Speaking & faculty fees$190%
  • Food & beverage$9,54498%
  • Education$1431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,706 in reported general payments places this provider in the 70th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina

Medicare billing

Part B allowed, 2024
$241,086
Medicare patients
795
Services billed
1,680

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5018$444,661
GammakedImmune Globul G/Gly/Iga Avg 4617$322,840
TecfideraDimethyl Fumarate14$122,636
BetaseronInterferon Beta-1b11$107,496
Avonex Pen (4 Pack)Interferon Beta-1a12$97,599
NuplazidPimavanserin Tartrate13$62,138
RytaryCarbidopa/Levodopa20$41,487
NuedextaDextromethorphan Hbr/Quinidine13$21,259
Emgality PenGalcanezumab-Gnlm19$19,634
Ajovy AutoinjectorFremanezumab-Vfrm19$18,708
Aimovig AutoinjectorErenumab-Aooe17$16,517
Memantine Hcl284$12,724
Rivastigmine46$11,346
Carbidopa-LevodopaCarbidopa/Levodopa180$6,878
Donepezil Hcl496$6,876

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$311$122,63614 claims
BayerBetaseron$17$107,49611 claims
Acadia Pharmaceuticals IncNuplazid$333$62,13813 claims
Amneal Pharmaceuticals LLCRytary$15$41,48720 claims
Avanir Pharmaceuticals, Inc.Nuedexta$69$21,25913 claims
PfizerDilantin$483$4,16615 claims
Lilly USA, LLCOlanzapine$49$46820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 270 neurology providers in South Carolina.

Other neurology in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →